Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: A clinicopathologic and prognostic study

International Journal of Gynecological Cancer

Volumn 15, Issue 4, 2005, Pages 646-656

  Tangjitgamol, S ^a   Ramirez, P T ^a   Sun, C C ^a   See, H T ^a   Jhingran, A ^a   Kavanagh, J J ^a   Deavers, Michael T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

COX 2; EGFR; HER 2 neu; Neuroendocrine cervical carcinoma; VEGF

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RADIOSENSITIZING AGENT; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 22544442174     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00121.x     Document Type: Article

References (46)

1. Albores-Saavedra J, Gersell D, Gilks CB et al., Terminology of endocrine tumors of the uterine cervix. Results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 1997;121:34-9
2. van Nagell JR, Powell DE, Gallion HH et al., Small cell carcinoma of the uterine cervix. Cancer 1988;62:1586-93.
3. Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer 1994;73:672-7.
4. Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol 2003;22:226-30.
5. Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine [corrected] carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol 1997;21:905-14.
6. Sevin BU, Method MW, Nadji M, Lu Y, Averette HA. Efficacy of radical hysterectomy as treatment for patients with small cell carcinoma of the cervix. Cancer 1996;77:1489-93.
7. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 2003;97:568-74.
8. Krivak T, McBroom JW, Sundborg MJ, Crothers B, Parker MF. Large cell neuroendocrine cervical carcinoma: a report of two cases and review of literature. Gynecol Oncol 2001;82:187-91.
9. Weed JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg 2003;197:44-51.
10. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl. 4):S9-15.
11. Gaffney DK, Haslam D, Tsodikov A et al., Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-8.
12. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002;87:84-9.
13. Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989;33: 146-50.
14. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996;78:433-40.
15. Scambia G, Ferrandina G, Distefano M, D'Agostino G, Benedetti-Panici P, Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett 1998;123:135-9.
16. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993;13:1133-7.
17. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 1992; 52:3089-93.
18. Kaseda S, Ueda M, Ozawa S, Ishihara T, Abe O, Shimizu N. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 1989;42:16-20.
19. Schneider PM, Hung MC, Chiocca SM et al. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 1989;49:4968-71.
20. Gugger M, Burckhardt E, Kappeler A, Hirsiger H, Laissue JA, Mazzucchelli L. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J Pathol 2002;196:408-15.
21. Araki K, Ishii G, Yokose T et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-80.
22. Potti A, Willardson J, Forseen C et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 2002;36:257-61.
23. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9(Suppl. 2):28-35.
24. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
25. Kaiser U, Hofmann J, Schilli M et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64.
26. Bhattacharya D, Redkar A, Mittra I, Sutaria U, MacRae KD. Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo. Br J Cancer 1997;75:554-8.
27. Ciocca DR, Puy LA, Fasoli LC. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix. Cancer Res 1989;49:4298-304.
28. Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins YL, DeLange RJ. Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina, and vulva. Gynecol Oncol 1983;15:27-31.
29. Potish RA, Twiggs LB, Adcock LL, Prem KA, Savage JE, Leung BS. Prognostic importance of progesterone and estrogen receptors in cancer of the uterine cervix. Cancer 1986;58:1709-13.
30. Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol 2004;93:27-33.
31. Kulkarni S, Rader JS, Zhang F et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 2001;7:429-34.
32. Ferrandina G, Lauriola L, Distefano MG et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-81.
33. Marrogi AJ, Travis WD, Welsh JA et al. Nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
34. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
35. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
36. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336-47.
37. Lee IJ, Park KR, Lee KK et al. Prognostic value of vascular endothelial growth factor in stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-79.
38. Tjalma W, Weyler J, Weyn B et al. The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000; 92:251-7.
39. Ryu S, Oka K, Tsuujii H, Suzuki Y, Nakano T. Platelet-derived endothelial cell growth factor as a prognostic factor for radiotherapy outcome in patients with adenocarcinoma of the uterine cervix. Gynecol Oncol 2003;89:414-9.
40. Salomon DS, Kim N, Saeki T, Ciardiello F. Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells 1990;2:389-97.
41. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-67.
42. Lee CM, Lee RJ, Hammond E et al. Expression of HER2neu (c-erbB2) and epidermal growth factor receptor (EGFR) in carcinoma of the cervix: correlation with clinical characteristics and prognosis [abstract]. Int J Radiat Oncol Biol Phys 2003;57:S192-3.
43. Straughn JM Jr, Richter HE, Conner MG, Meleth S, Barnes MN. Predictors of outcome in small cell carcinoma of the cervix-a case series. Gynecol Oncol 2001; 83:216-20.
44. Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol 2003;34:635-8.
45. Horvai AE, Li L, Xu Z, Kramer MJ, Jablons DM, Treseler PA. Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. Arch Pathol Lab Med 2003;127:465-9.
46. Bellone S, Palmieri M, Gokden M et al. Selection of HER-2/neu-positive tumor cells in early stage cervical canceer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003;91:231-40.